Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic strategy for managing metabolic syndromes. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin secretion and suppressing glucagon secretion. GLP-1 agents possess promising therapeutic efficacy in treating type 2